Insiders made 11 unusual buys across 9 small company tickers in the week through Sep 25, out of 61 buys overall. The disclosed names were $ENHA at $6.99M, $INBX at $500K and $EPSN at $137K. Three of those names are in the Insider Trading book.

๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 3,000 shares @ $101.70
Total: $305K
Filed Sep 24, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 1,500 shares @ $98.88
Total: $148K
Filed Sep 24, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 2,176 shares @ $99.60
Total: $217K
Filed Sep 24, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 3,324 shares @ $98.87
Total: $329K
Filed Sep 24, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Kayyem Jon Faiz, Director
BOUGHT: 5,000 shares @ $100.00
Total: $500K
Filed Sep 22, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Kayyem Jon Faiz, Director
BOUGHT: 5,000 shares @ $100.00
Total: $500K
Filed Sep 15, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
Inhibrx Insiders Report About $3.5 Million of Open-Market Stock Purchases Three Inhibrx insiders filed Form 4s reporting open-market purchases of 32,500 shares...
https://www.narrowit.com/news/inhibrx-insiders-buy-3-5-million-stock-form-4-2026-09-08
#InhibrxBiosciences #INBX #Form4 #InsiderBuying
๐ข $INBX โ Kayyem Jon Faiz, Director
BOUGHT: 5,000 shares @ $113.52
Total: $568K
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ FORSYTH DOUGLAS, Director
BOUGHT: 2,500 shares @ $114.65
Total: $287K
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ $INBX 10-Q โ what changed
MD&A now says: "20 ozekibart (INBRX-109) Ozekibart is a precisely engineered tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types."
๐ Full
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 9,681 shares @ $112.28
Total: $1.1M
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 1,219 shares @ $111.88
Total: $136K
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 1,100 shares @ $107.12
Total: $118K
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 6,605 shares @ $100.64
Total: $665K
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
๐ข $INBX โ Lappe Mark, Chief Executive Officer
BOUGHT: 5,895 shares @ $99.29
Total: $585K
Filed Sep 7, 2026 ยท 8:00pm ET
๐ History & trend โ https://www.formdelta.com/ticker/INBX
#INBX Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study